Curis CA-4948-101 (Primary Central Nervous System Lymphoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called CA-4948 is a safe and effective option for people with PCNSL. We want to know how well it works when it is combined with a drug called ibrutinib, which is commonly used to treat PCNSL.
Primary Central Nervous System Lymphoma (PCNSL)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with PCNSL by biopsy or imaging
- Have disease that worsened or came back after standard therapy
- Have a life expectancy of more than 3 months
For more information, contact the study team at 919-684-5301.
What is Involved?
If you choose to join the study, you will:
- Take the study drug tablets by mouth twice daily
- Take ibrutinib tablets by mouth once a day (preferably in the morning)
- Have physical exams and blood tests
- Have heart images taken
- Have electrocardiograms (ECGs)
- Have CT/MRI scans
- Have eye examinations
- Have a lumbar puncture (spinal tap)
You will have assessments of how you are doing with the study drug regimen at the end of every "cycle." A cycle is a 28-day period in which you will take the study drug and ibrutinib. The number of cycles you do in the study will depend on how well you respond to the study drug regimen. You can continue for as long as you and your study doctor believe that you are receiving a positive benefit.
Study Details
